Laura van ‘t Veer, chief research officer for Agendia BV, Amsterdam, Netherlands, has received the 2007 Breast Cancer Research Foundation award from the Pink Ribbon Breast Cancer Research Foundation. 

van ‘t Veer and her colleagues were recognized for their work on the European MINDACT trial, in which specific predictive aspects of MammaPrint breast cancer prognosis assay are further tested. van ‘t Veer’s work helped Agendia get FDA clearance for its MammaPrint breast cancer test.

Agendia focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling.

The Breast Cancer Research Foundation provides funding for innovative clinical and genetic research for leading medical centers worldwide.